ReviewNanomedicine (London, England)2012
Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics.
Review in Nanomedicine (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 158 citations in OpenAlex.
- Rational Design of New Biocompatible Near-Infrared Conjugated Polymer Nanoparticles for Biomedical Applications.Macromolecules · 2026Article
- Advances in Optical Contrast Agents for Medical Imaging: Fluorescent Probes and Molecular Imaging.Journal of imaging · 2025Review
- Optical molecular imaging technology and its application in precise surgical navigation of liver cancer.Theranostics · 2025Review
- Article
- Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis.Biomaterials research · 2024Review
- Neurotoxin-Derived Optical Probes for Biological and Medical Imaging.Molecular imaging and biology · 2023Review
- Multimodal imaging needle combining optical coherence tomography and fluorescence for imaging of live breast cancer cells labeled with a fluorescent analog of tamoxifen.Journal of biomedical optics · 2022Article
- Advanced Optical Imaging-Guided Nanotheranostics towards Personalized Cancer Drug Delivery.Nanomaterials (Basel, Switzerland) · 2022Review
- Near-infrared fluorescence guided surgery: State of the evidence from a health technology assessment perspective.Frontiers in surgery · 2022Review
- Spectral- and Polarization-Dependent Scattering of Gold Nanobipyramids for Exogenous Contrast in Optical Coherence Tomography.Nano letters · 2021Article
- Enhanced Detection of Desmoplasia by Targeted Delivery of Iron Oxide Nanoparticles to the Tumour-Specific Extracellular Matrix.Pharmaceutics · 2021Article
- Size-controlled bimodalScience and technology of advanced materials · 2021Article
- Nanobodies asRSC chemical biology · 2021Review
- Activatable Nanoparticles: Recent Advances in Redox-Sensitive Magnetic Resonance Contrast Agent Candidates Capable of Detecting Inflammation.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Glutathione-responsive disassembly of disulfide dicyanine for tumor imaging with reduction in background signal intensity.Theranostics · 2020Article
- Immune-mediated ECM depletion improves tumour perfusion and payload delivery.EMBO molecular medicine · 2019Article
- Optical Imaging of Triple-Negative Breast Cancer Cells in Xenograft Athymic Mice Using an ICAM-1-Targeting Small-Molecule Probe.Molecular imaging and biology · 2019Article
- RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Affibody-Indocyanine Green Based Contrast Agent for Photoacoustic and Fluorescence Molecular Imaging of B7-H3 Expression in Breast Cancer.Bioconjugate chemistry · 2019Article
- Synthesis and investigation of phthalocyanine-biotin conjugates.Journal of porphyrins and phthalocyanines · 2019Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over the last three decades, our understanding of the molecular changes associated with cancer development and progression has advanced greatly. This has led to new cancer therapeutics targeted against specific molecular pathways; such therapies show great promise to reduce mortality, in part by enabling physicians to tailor therapy for patients based on a molecular profile of their tumor. Unfortunately, the tools for definitive cancer diagnosis - light microscopic examination of biopsied tissue stained with nonspecific dyes - remain focused on the analysis of tissue ex vivo. There is an important need for new clinical tools to support the molecular diagnosis of cancer. Optical molecular imaging is emerging as a technique to help meet this need. Targeted, optically active contrast agents can specifically label extra- and intracellular biomarkers of cancer. Optical images can be acquired in real time with high spatial resolution to image-specific molecular targets, while still providing morphologic context. This article reviews recent advances in optical molecular imaging, highlighting the advances in technology required to improve early cancer detection, guide selection of targeted therapy and rapidly evaluate therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.